Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls - 07/08/11

Supported by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract nos. N01 AI40029 and N01 AI40033, as well as the Clinical Translational Scientific Award UL1 RR025780 (National Jewish) and UL1 RR025758-01 from the National Center for Research Resources, National Institutes of Health, to the Harvard Catalyst Clinical and Translational Science Center (Harvard Catalyst). |
|
Disclosure of potential conflict of interest: L. Schneider has received research support from the NIH/NIAID Atopic Dermatitis Vacinnia Network. A. Weinberg has received grants and consulting fees from Merck & Co. H. Oettgen is a consultant and scientific advisor for Schering Plough, is a consultant for Genentech, and has received research support from Novartis. The rest of the authors have declared that they have no conflict of interest. |
Vol 126 - N° 6
P. 1306 - décembre 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?